Summary

Eligibility
for people ages 18-123 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations

Official Title

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Details

Eligible participants will be those diagnosed with unresectable, locally advanced or metastatic histologically documented non-squamous NSCLC with HER2 exons 19 or 20 mutations and who are treatment-naïve for palliative intent systemic therapy for locally advanced or metastatic disease. The study aims to evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) as compared with Standard of Care treatment (Investigator's choice of cisplatin or carboplatin + pembrolizumab + pemetrexed). This study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse or simply to live longer, compared to patients receiving standard of care treatment. This study is also looking to see how the treatment and the cancer affects patients' quality of life.

Keywords

Locally Advanced or Metastatic Non-Small Cell Lung Cancer DS-8201a HER2 exon 19 or 20 mutations ERBB2 gene (coding for the HER2 protein) T-DXd Trastuzumab Deruxtecan Locally advanced and unresectable non-squamous NSCLC Metastatic non-squamous NSCLC Non-small cell lung cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung Carboplatin Pembrolizumab Trastuzumab Pemetrexed Cisplatin

Eligibility

You can join if…

Open to people ages 18-123

  • Participants at least 18 years of age
  • Locally advanced not amenable to curative therapy, or metastatic disease
  • Histologically documented non-squamous NSCLC with HER2 mutation in exons 19 or 20 by tissue NGS or ctDNA
  • Treatment-naïve for palliative intent systemic therapy for locally advanced or metastatic disease
  • Left ventricular ejection fraction (LVEF) ≥ 50%
  • Measurable disease assessed by Investigator based on RECIST 1.1
  • Protocol-defined adequate organ function including cardiac, renal, hepatic function
  • ECOG 0-1
  • Having tumour tissue available for central testing

You CAN'T join if...

  • Tumors with targetable alterations to EGFR (or other targetable mutations including but not limited to ALK, if routinely tested as a targetable alteration with approved available therapy)
  • Any clinically active brain metastases; previously treated brain metastases allowed
  • Active autoimmune or inflammatory disorders
  • Medical history of myocardial infarction within 6 months prior to randomization
  • History of non-infectious pneumonitis/ILD, current or suspected ILD
  • Lung-specific intercurrent clinical significant severe illness
  • Contraindication to platinum-based doublet chemotherapy or pembrolizumab

Locations

  • Research Site
    San Francisco California 94143 United States
  • Research Site
    Vancouver British Columbia V5Z 4E6 Canada

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
AstraZeneca
ID
NCT05048797
Phase
Phase 3
Study Type
Interventional
Last Updated